Goldman Sachs Maintains Buy on CareDx, Raises Price Target to $16
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Matthew Sykes maintains a Buy rating on CareDx (NASDAQ:CDNA) and raises the price target from $14 to $16.
July 17, 2024 | 4:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Goldman Sachs analyst Matthew Sykes maintains a Buy rating on CareDx and raises the price target from $14 to $16.
The Buy rating and increased price target from a reputable analyst at Goldman Sachs is likely to boost investor confidence in CareDx, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100